Dynamic RODEO Images Show Laser Ablation of a Small Breast Tumor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

Serial dynamic RODEO (Rotating Delivery of Excitation Off-resonance) magnetic resonance images (top left to bottom right) generated at approximately 1- to 2-minute intervals during the course of interstitial laser photocoagulation treatment of a small breast cancer. Prior to laser treatment, pre- and post-gadolinium contrast RODEO images were generated to allow accurate placement of a needle tip into the lesion. A bare-tip laser fiber was then inserted into the needle and connected to the laser. The laser tip was pre-charred; then 3 watts of continuous power were applied for 10 minutes. The top left image is before initiation of laser treatment. The next image (to the right of the top left image) depicts the zone of pre-charring. As the laser ablation progresses, the hypointense zone increases in size. The final dynamic image on the bottom right shows an approximately 1.4 cm zone of ablation. Images courtesy of Dr. Steven E. Harms, professor of radiology, University of Arkansas for Medical Sciences.

Serial dynamic RODEO (Rotating Delivery of Excitation Off-resonance) magnetic resonance images (top left to bottom right) generated at approximately 1- to 2-minute intervals during the course of interstitial laser photocoagulation treatment of a small breast cancer. Prior to laser treatment, pre- and post-gadolinium contrast RODEO images were generated to allow accurate placement of a needle tip into the lesion. A bare-tip laser fiber was then inserted into the needle and connected to the laser. The laser tip was pre-charred; then 3 watts of continuous power were applied for 10 minutes. The top left image is before initiation of laser treatment. The next image (to the right of the top left image) depicts the zone of pre-charring. As the laser ablation progresses, the hypointense zone increases in size. The final dynamic image on the bottom right shows an approximately 1.4 cm zone of ablation. Images courtesy of Dr. Steven E. Harms, professor of radiology, University of Arkansas for Medical Sciences.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content